American Journal of Ophthalmology
Volume 147, Issue 5 , Pages 831-837 , May 2009

Effects of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Attributable to Age-related Macular Degeneration

  • Simon P. Rothenbuehler

      Affiliations

    • Bern Photographic Reading Center, Universitätsklinik für Augenheilkunde, Inselspital, University Bern, Bern, Switzerland
    • Corresponding Author InformationInquiries to Simon P. Rothenbuehler, Bern Photographic Reading Center, Universitätsklinik für Augenheilkunde, Inselspital, University Bern, CH-3010 Bern, Switzerland
    • ,
  • David Waeber

      Affiliations

    • Universitätsklinik für Augenheilkunde, Inselspital, University Bern, Bern, Switzerland
    • Bern Photographic Reading Center, Universitätsklinik für Augenheilkunde, Inselspital, University Bern, Bern, Switzerland
    • ,
  • Christian K. Brinkmann

      Affiliations

    • Universitätsklinik für Augenheilkunde, Inselspital, University Bern, Bern, Switzerland
    • ,
  • Sebastian Wolf

      Affiliations

    • Universitätsklinik für Augenheilkunde, Inselspital, University Bern, Bern, Switzerland
    • Bern Photographic Reading Center, Universitätsklinik für Augenheilkunde, Inselspital, University Bern, Bern, Switzerland
    • ,
  • Ute E.K. Wolf-Schnurrbusch

      Affiliations

    • Universitätsklinik für Augenheilkunde, Inselspital, University Bern, Bern, Switzerland
    • Bern Photographic Reading Center, Universitätsklinik für Augenheilkunde, Inselspital, University Bern, Bern, Switzerland

,Accepted 3 December 2008.

References 

  1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900–1901
  2. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–485
  3. TAP Study Group. Photodynamic therapy of subfoveoal choroidal neovascularization in age-related macular degeneration with Verteporfin (One-year results of 2 randomized clinical trials - TAP Report No. 1). Arch Ophthalmol. 1999;117:1329–1345
  4. VIP Study Group, TAP Study Group. Verteprofin therapy of subfoveal choroidal neovascularization in age-related macular degeneration (Meta-analysis of 2-year results in three randomized clinical trials: treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study Report No. 4). Retina. 2004;24:1–11
  5. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials-TAP Report No. 2. Arch Ophthalmol. 2001;119:198–207
  6. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators; Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002;22:6–18
  7. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855–868
  8. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393–403
  9. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929–1934
  10. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64:162–169
  11. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3186–3193
  12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
  13. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–248
  14. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444
  15. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–583

PII: S0002-9394(08)00922-7

doi: 10.1016/j.ajo.2008.12.005

American Journal of Ophthalmology
Volume 147, Issue 5 , Pages 831-837 , May 2009

Article Tools

* Image Usage & Resolution